A Prospective Multicenter Post Approval Study of the ReShape™ Integrated Dual Balloon System in Obese Subjects

Obesity Clinical Trial

— ReShapePAS  

Official title:

A Prospective Multicenter Post Approval Study of the ReShape™ Integrated Dual Balloon System in Obese Subjects

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT02927665
• Other study ID #: ReShape Post Approval Study
• Status: Active, not recruiting
• Start date: September 2016
• Est. completion date: December 2019

Study information

• Verified date: March 2019
• Source: ReShape Lifesciences
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The ReShape Post Approval Study is a prospective multicenter study of the ReShape(TM) Integrated Dual Balloon System in Obese Subjects.

Description:

The ReShape Post Approval Study is a post-approval, multicenter, single arm, open label clinical study intended to collect valid scientific evidence regarding the safety and efficacy of the ReShape Dual Balloon as an adjunct to diet and exercise in the treatment of BMI 30-40 subjects with one or more obesity-related comorbid conditions in a commercial clinical setting.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 186
• Est. completion date: December 2019
• Est. primary completion date: November 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 22 Years and older

Eligibility

Inclusion Criteria:

1. Ages 22 and older

2. Baseline BMI 30 - 40

3. Failed weight reduction with diet and exercise alone

4. One or more obesity-related comorbid conditions

5. If female of child bearing potential, willing to avoid pregnancy during course of treatment

Exclusion Criteria:

1. Prior gastrointestinal surgery with sequelae, i.e. obstruction, and/or adhesive peritonitis or known abdominal adhesions

2. Prior open or laparoscopic bariatric surgery.

3. Any inflammatory disease of the gastrointestinal tract including esophagitis, gastric ulceration, duodenal ulceration, cancer or specific inflammation such as Crohn's disease.

4. Potential upper gastrointestinal bleeding conditions such as esophageal or gastric varices, congenital or acquired intestinal telangiectasis, or other congenital anomalies of the gastrointestinal tract such as atresias or stenoses.

5. A gastric mass.

6. A hiatal hernia > 5 cm or = 5 cm with associated severe or intractable gastro-esophageal reflux symptoms.

7. A structural abnormality in the esophagus or pharynx such as a stricture or diverticulum that could impede passage of the delivery catheter and/or an endoscope.

8. Achalasia or any other severe esophageal motility disorder that may pose a safety risk during the removal of the device

9. Severe coagulopathy

10. Hepatic insufficiency or cirrhosis

11. Serious or uncontrolled psychiatric illness or disorder that could compromise patient understanding of or compliance with follow up visits and removal of the device after 6 months.

12. Alcoholism or drug addiction.

13. Patients unwilling to participate in an established medically-supervised diet and behavior modification program, with routine medical follow-up.

14. Patients receiving daily prescribed treatment with aspirin, anti-inflammatory agents, anticoagulants or other gastric irritants.

15. Patients who are unable or unwilling to take prescribed proton pump inhibitor medication for the duration of the device implant.

16. Patients who are known to have, or suspected to have, an allergic reaction to materials contained in the system.

17. Patients who have ever developed a serotonin syndrome and are currently taking any drug known to affect the levels of serotonin in the body [e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs)] should not undergo placement of the device.

18. Patients who are pregnant or breast-feeding.

19. Significant endoscopic abnormalities immediately prior to device insertion.

Related Conditions & MeSH terms

• Obesity

Intervention

Device:
• Reshape Integrated Dual Balloon

Locations

Country	Name	City	State
United States	Barrington Surgeons	Barrington	Illinois
United States	JourneyLite Physicians	Cincinnati	Ohio
United States	Digestive Health Specialists of the Southeast	Dothan	Alabama
United States	Gastrointestinal Associates, P.C.	Knoxville	Tennessee
United States	The Gastro Clinic	Lafayette	Louisiana
United States	MidSouth Bariatrics	Memphis	Tennessee
United States	Surgical Specialist of Louisiana	Metairie	Louisiana
United States	Christiana Institute of Advanced Surgery	Newark	Delaware
United States	New York Bariatric Group	Roslyn Heights	New York
United States	Washington University	Saint Louis	Missouri
United States	Salem General Surgery	Salem	Ohio
United States	Sage Bariatric Institute	San Antonio	Texas
United States	Eviva	Shoreline	Washington
United States	North Jersey Laparoscopic Associates	Teaneck	New Jersey

Sponsors (1)

Lead Sponsor	Collaborator
ReShape Lifesciences

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety of ReShape Dual Balloon Treatment	Safety of ReShape Dual Balloon Treatment using a composite endpoint consisting of all device- and/or procedure-related SAEs	24 weeks